Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Axsome Therapeutics (AXSM) through the VizualStocks API.
Revenue recognized during the period from achieved Auvelity partner regulatory milestones. This excludes net product sales and potential future milestone amounts.
auvelityMilestoneRevenueNet sales of Auvelity, Axsome’s dextromethorphan-bupropion treatment, recognized during the period after sales deductions. This product-sales disaggregation excludes separately recognized licensing and milestone revenue.
auvelityNetProductSalesApproximate number of total prescriptions for Auvelity reported by Axsome for the quarter. These are prescriptions, not unique patients or new-to-brand starts, and retain the issuer’s rounded as-reported counts.
auvelityPrescriptionsRevenue recognized during the period from licensing Sunosi commercialization rights to partners, including the 2023 upfront Pharmanovia payment for Europe and specified Middle East and North Africa territories. This excludes product supply, royalties and separately identified milestone revenue.
sunosiLicenseRevenueRevenue recognized during the period when Sunosi partner development or regulatory milestones satisfy the issuer’s recognition criteria. This records earned revenue, excluding potential future contractual milestone amounts.
sunosiMilestoneRevenueNet sales of Sunosi (solriamfetol) recognized by Axsome during the period, including direct-market sales and product supplied to licensees. This excludes royalties, license payments and milestone revenue from Sunosi partners.
sunosiNetProductSalesApproximate number of Sunosi prescriptions in the United States reported by Axsome for the quarter. These are prescriptions rather than unique patients and retain the issuer’s rounded as-reported counts.
sunosiPrescriptionsRevenue recognized during the period from royalties on Sunosi sales by licensees in out-licensed territories. This excludes Axsome’s own Sunosi product sales and separately identified license or milestone payments.
sunosiRoyaltyRevenueNet sales of Symbravo (meloxicam-rizatriptan), Axsome’s acute migraine treatment, recognized during the period after sales deductions. Commercial sales began in June 2025.
symbravoNetProductSalesApproximate number of Symbravo prescriptions reported by Axsome for the quarter following its June 2025 launch. These are prescriptions rather than unique patients and retain the issuer’s rounded as-reported counts.
symbravoPrescriptions